Craig M. Crews
| Craig M. Crews | |
|---|---|
| Born | June 1, 1964 (age 52) |
| Fields | Chemical Biology |
| Institutions | Yale University |
| Alma mater |
University of Virginia Harvard University |
| Doctoral advisors |
Raymond L. Erikson Stuart Schreiber (Postdoctoral Advisor) |
| Known for | Controlled Proteostasis Carfilzomib |
| Notable awards |
|
UCB-Ehrlich Award for Excellence in Medicinal Chemistry (2014)
Craig M. Crews, Ph.D. (born June 1, 1964) is an American scientist at Yale University. As the Lewis B. Cullman Professor of , Crews also holds joint appointments in the departments of Chemistry and Pharmacology. He currently serves as an Editor of Cell Chemical Biology and is the Executive Director of the Yale Center for Molecular Discovery. His research interests focus on Chemical Biology, particularly on controlled proteostasis, which has led to the development of the FDA approved anti-cancer drug Carfilzomib (Kyprolis®).
Crews graduated from the University of Virginia in 1986 with a bachelor's degree in Chemistry, after which he performed research at the University of Tübingen as a German Academic Exchange Service (DAAD) Fellow. As a graduate student in the laboratory of Raymond Erikson at Harvard University, Crews purified and cloned the MAP kinase kinase MEK1, a key kinase that controls cell growth. He subsequently worked in the research group of Stuart Schreiber as a Cancer Research Institute Fellow before joining the faculty of Yale University as an assistant professor in Molecular, Cellular, and Developmental Biology.
Crews studies controlled proteostasis, i.e., the small molecule control of protein turnover. His lab’s synthesis and mode of action studies of the natural product epoxomicin revealed that it is a potent and selective proteasome inhibitor. Subsequent medicinal chemistry efforts produced the epoxyketone containing proteasome inhibitor YU101, which served as the basis for the multiple myeloma drug Carfilzomib (Kyprolis®). In 2001, Crews developed (in collaboration with Ray Deshaies) PROTACs (Proteolysis Targeting Chimeras), a new technology to induce proteolysis. PROTACs are dimeric molecules that recruit targeted intracellular proteins to the cellular quality control machinery (i.e., an E3 ubiquitin ligase) for subsequent removal by the proteasome.
...
Wikipedia